156 related articles for article (PubMed ID: 1087561)
1. [Immunosuppressive treatment of rheumatic diseases. Experimental bases of a rational concept of therapeutic approach (author's transl)].
Lemmel EM; Botzenhardt U
Arzneimittelforschung; 1976; 26(7):1281-95. PubMed ID: 1087561
[TBL] [Abstract][Full Text] [Related]
2. Comparative study on the immunosuppressive and lympholytic activity of optical isomers of cyclophosphamide.
Tchórzewski H; Soszyńska W; Andrzejewski W; Pankiewicz K; Stec WJ
Arch Immunol Ther Exp (Warsz); 1983; 31(3):329-33. PubMed ID: 6228204
[TBL] [Abstract][Full Text] [Related]
3. Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/W murine model of systemic lupus erythematosus.
Austin HA; Patel AD; Cadena CA; Boumpas DT; Balow JE
J Rheumatol; 1997 Jan; 24(1):61-8. PubMed ID: 9002012
[TBL] [Abstract][Full Text] [Related]
4. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment.
Murphy G; Lisnevskaia L; Isenberg D
Lancet; 2013 Aug; 382(9894):809-18. PubMed ID: 23972423
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression and the rheumatic diseases.
Denman AM
Ann Rheum Dis; 1982; 41 Suppl 1(Suppl 1):3-8. PubMed ID: 6978108
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of 6-mercaptopurine and cyclophosphamide on autoimmune phenomena in NZB mice.
Lemmel E; Hurd ER; Ziff M
Clin Exp Immunol; 1971 Feb; 8(2):355-62. PubMed ID: 4102260
[TBL] [Abstract][Full Text] [Related]
7. [Modification of immune reactions by antigen-immunosuppressive agent conjugates. V. Studies on antigen-specific activity of 6-mercaptopurine bovine gamma globulin conjugates on the humoral immune response in rabbits].
Drössler K; Ambrosius H
Acta Biol Med Ger; 1977; 36(2):257-65. PubMed ID: 71798
[TBL] [Abstract][Full Text] [Related]
8. Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice.
Mathian A; Gallegos M; Pascual V; Banchereau J; Koutouzov S
Eur J Immunol; 2011 Mar; 41(3):863-72. PubMed ID: 21312191
[TBL] [Abstract][Full Text] [Related]
9. Elimination of tumor-enhancing cells by cyclophosphamide and its relevance to cyclophosphamide therapy of the murine mammary tumor.
Nakajima H; Abe S; Masuko Y; Tsubouchi J; Yamazaki M; Mizuno D
Gan; 1981 Oct; 72(5):723-31. PubMed ID: 7327373
[TBL] [Abstract][Full Text] [Related]
10. Practical use of immunosuppressive drugs in autoimmune rheumatic diseases.
De Jesus A; Talal N
Crit Care Med; 1990 Feb; 18(2 Suppl):S132-7. PubMed ID: 2298028
[TBL] [Abstract][Full Text] [Related]
11. Bromocriptine in rheumatic and autoimmune diseases.
McMurray RW
Semin Arthritis Rheum; 2001 Aug; 31(1):21-32. PubMed ID: 11503136
[TBL] [Abstract][Full Text] [Related]
12. [The role of regulatory T-cells in autoimmune rheumatic diseases].
Nasonov EL; Bykovskaia SN
Vestn Ross Akad Med Nauk; 2006; (9-10):74-82. PubMed ID: 17111929
[TBL] [Abstract][Full Text] [Related]
13. Long-lived plasma cells and their contribution to autoimmunity.
Hoyer BF; Manz RA; Radbruch A; Hiepe F
Ann N Y Acad Sci; 2005 Jun; 1050():124-33. PubMed ID: 16014527
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive agents and plasmapheresis in immunological disorders.
Tsokos GC; Balow JE
J Immunopharmacol; 1985; 7(1):1-15. PubMed ID: 3891866
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses.
Ahmed AR; Hombal SM
J Am Acad Dermatol; 1984 Dec; 11(6):1115-26. PubMed ID: 6392368
[TBL] [Abstract][Full Text] [Related]
16. [Modification of the immune reaction by antigen-immunosuppressive-agent conjugates. II. Immunogenicity of antigen-immunosuppressive-agent conjugates].
Drössler K; Fiebig H; Ambrosius H
Acta Biol Med Ger; 1976; 35(12):1687-97. PubMed ID: 69373
[TBL] [Abstract][Full Text] [Related]
17. Immunological enhancement with a low dose of cyclophosphamide in aged mice.
Ishiyama N; Utsuyama M; Kitagawa M; Hirokawa K
Mech Ageing Dev; 1999 Nov; 111(1):1-12. PubMed ID: 10576603
[TBL] [Abstract][Full Text] [Related]
18. Acceleration of autoimmune diabetes by cyclophosphamide is associated with an enhanced IFN-gamma secretion pathway.
Ablamunits V; Quintana F; Reshef T; Elias D; Cohen IR
J Autoimmun; 1999 Dec; 13(4):383-92. PubMed ID: 10585754
[TBL] [Abstract][Full Text] [Related]
19. Antibody plaque reduction in vitro and in vivo: a rapid assay for immunosuppressive agents.
Gavin J; Waterbury W; Freidman H
Transplant Proc; 1969 Mar; 1(1):413-5. PubMed ID: 4944252
[No Abstract] [Full Text] [Related]
20. Selected problems in immunosuppressive therapy.
Rondio H
Mater Med Pol; 1974; 6(1):34-40. PubMed ID: 4613962
[No Abstract] [Full Text] [Related]
[Next] [New Search]
